Nervous Child 1943;2:217-50
Combining with other weight loss agents Tesofensine + GLP-1 agonists (theoretical): Different mechanisms = potential synergy Tesofensine: Metabolic + CNS appetite GLP-1s : Strong appetite + gastric slowing Could enhance weight loss to 20-25%+ BUT: No clinical data, significant risks Not recommended without supervision Potential combination benefits: Address multiple pathways Overcome plateaus Better than either alone (theoretically) Metabolic boost + strong appetite suppression Maximum fat loss Combination risks: Compounded cardiovascular strain Unknown drug interactions Excessive weight loss risks Cost ($1,500-2,000/month) Safer alternatives to tesofensine combinations: Tirzepatide alone (15-22% loss, FDA approved) CagriSema (sema + cagrilintide, 15-25%) GLP-1 + lifestyle (safer, proven) Learn about peptide stacking strategies at SeekPeptides

Additional preconception measures include: Folic acid supplementation : 5 mg daily (higher dose than standard) should be commenced at least three months before conception and continued through the first 12 weeks of pregnancy to reduce neural tube defect risk Medication review : assessment of all medications for pregnancy safety, including blood pressure medications, cholesterol-lowering drugs, and other diabetes medications Retinopathy screening : diabetic eye screening should be current, as pregnancy can accelerate retinopathy progression Renal function assessment : baseline kidney function tests to identify any pre-existing diabetic nephropathy If you discover you are pregnant whilst taking Ozempic, contact your healthcare provider immediately do not wait for a scheduled appointment
With liraglutide requiring daily injections, site rotation becomes more important because the same areas get used much more frequently
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of injectable medications that mimic a gut hormone to reduce appetite, promote weight loss, and, increasingly, appear to dampen inflammation beyond their metabolic effects
This deficiency can be present from birth, termed as primary systemic carnitine deficiency, or can arise as a secondary condition due to specific metabolic disorders